Agenus Inc. (NASDAQ:AGEN - Get Free Report)'s share price passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.87 and traded as high as $3.84. Agenus shares last traded at $3.82, with a volume of 422,744 shares.
Analyst Ratings Changes
A number of research analysts have recently weighed in on the company. Robert W. Baird raised their target price on Agenus from $3.00 to $4.00 and gave the company a "neutral" rating in a report on Tuesday, May 13th. HC Wainwright reissued a "neutral" rating on shares of Agenus in a research report on Tuesday, May 13th. Wall Street Zen raised shares of Agenus from a "strong sell" rating to a "hold" rating in a report on Thursday, May 22nd. Finally, B. Riley reiterated a "buy" rating on shares of Agenus in a research note on Monday, April 21st. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $9.00.
Read Our Latest Report on AGEN
Agenus Stock Up 7.8%
The company has a market capitalization of $94.59 million, a PE ratio of -0.31 and a beta of 1.48. The stock has a 50-day moving average of $2.58 and a 200 day moving average of $2.87.
Agenus (NASDAQ:AGEN - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The biotechnology company reported ($1.03) earnings per share for the quarter, beating the consensus estimate of ($1.61) by $0.58. The company had revenue of $24.07 million during the quarter, compared to analysts' expectations of $26.38 million. Equities analysts forecast that Agenus Inc. will post -12.55 EPS for the current fiscal year.
Hedge Funds Weigh In On Agenus
A number of large investors have recently bought and sold shares of the stock. B. Riley Financial Inc. bought a new stake in shares of Agenus during the 4th quarter valued at $2,074,000. Siren L.L.C. bought a new position in Agenus during the 1st quarter valued at about $752,000. AQR Capital Management LLC boosted its holdings in shares of Agenus by 3,080.3% during the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company's stock valued at $664,000 after acquiring an additional 427,604 shares during the last quarter. Gilead Sciences Inc. bought a new stake in shares of Agenus in the fourth quarter worth approximately $635,000. Finally, Northern Trust Corp raised its holdings in shares of Agenus by 14.8% during the fourth quarter. Northern Trust Corp now owns 208,933 shares of the biotechnology company's stock valued at $572,000 after purchasing an additional 26,870 shares during the last quarter. 61.46% of the stock is owned by hedge funds and other institutional investors.
About Agenus
(
Get Free Report)
Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Recommended Stories
Before you consider Agenus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Agenus wasn't on the list.
While Agenus currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
